Abstract | BACKGROUND: Co-administration of a fibrate and statin is an effective treatment option for patients with multiple lipid abnormalities, yet adequate long-term safety and efficacy data are lacking. OBJECTIVE: METHODS: RESULTS: Across the controlled studies and the extension study, 2201 patients received at least one dose of fenofibric acid + statin for a median duration of 364 days. The most common adverse events were headache, upper respiratory tract infection, nasopharyngitis, and back pain, with the incidence of all adverse events being similar across all combination therapy treatment groups. Rhabdomyolysis or treatment-related death was not reported in any group. Combination therapy resulted in sustained improvements in multiple lipid parameters, including triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, non- high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and high-sensitivity C-reactive protein. CONCLUSION:
|
Authors | Harold E Bays, Peter H Jones, Syed M Mohiuddin, Maureen T Kelly, Hsiaoming Sun, Carolyn M Setze, Susan M Buttler, Darryl J Sleep, James C Stolzenbach |
Journal | Journal of clinical lipidology
(J Clin Lipidol)
Vol. 2
Issue 6
Pg. 426-35
(Dec 2008)
ISSN: 1933-2874 [Print] United States |
PMID | 21291776
(Publication Type: Journal Article)
|